Comparative Pharmacology
Head-to-head clinical analysis: MD 60 versus RENO DIP.
Peer-Reviewed Evidence
Head-to-head clinical analysis: MD 60 versus RENO DIP.
MD-60 vs RENO-DIP
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
MD-60 is a nonionic iodinated contrast agent. It attenuates X-rays by increasing the density of structures and organs, improving radiographic visualization.
RENO-DIP (dipyridamole) is a platelet aggregation inhibitor that inhibits adenosine deaminase and phosphodiesterase, leading to increased intracellular cyclic adenosine monophosphate (cAMP) and cyclic guanosine monophosphate (cGMP), and blocks adenosine reuptake, resulting in vasodilation and inhibition of platelet aggregation.
Intravenous administration, 60 mg/kg as a single dose over 30 min.
Hypertension: initial 10 mg orally once daily, titrate to 40 mg once daily. Heart failure: initial 2.5 mg orally twice daily, titrate to 20 mg twice daily as tolerated.
None Documented
None Documented
Terminal elimination half-life is 18–24 hours in patients with normal renal function (CrCl >90 mL/min); prolonged to >40 hours in moderate renal impairment (CrCl 30–60 mL/min), requiring dose adjustment.
Terminal elimination half-life is 2-4 hours in patients with normal renal function; prolonged to 15-30 hours in severe renal impairment (CrCl <30 mL/min).
Primarily renal elimination of unchanged drug (~60% within 24 hours) via glomerular filtration; biliary/fecal excretion accounts for ~30% as metabolites; ~10% undergoes enterohepatic recirculation.
Primarily renal excretion of unchanged drug (70%) via glomerular filtration and active tubular secretion; 20% excreted as metabolites in urine; 10% eliminated in feces via biliary secretion.
Category C
Category C
Radiocontrast Agent
Radiocontrast Agent